Literature DB >> 21613999

Perspective: test and treat this silent killer.

Brian R Edlin1.   

Abstract

Entities:  

Mesh:

Year:  2011        PMID: 21613999      PMCID: PMC4751873          DOI: 10.1038/474S18a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  5 in total

1.  Injection drug users: the overlooked core of the hepatitis C epidemic.

Authors:  Brian R Edlin; Michael R Carden
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

2.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

3.  Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-05-06       Impact factor: 17.586

4.  Update on the seroepidemiology of human immunodeficiency virus in the United States household population: NHANES III, 1988-1994.

Authors:  G M McQuillan; M Khare; J M Karon; C A Schable; D Vlahov
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-04-01

5.  Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000.

Authors:  Fan-Chen Tseng; Thomas R O'Brien; Mingdong Zhang; Alex H Kral; Betty A Ortiz-Conde; Jennifer Lorvick; Michael P Busch; Brian R Edlin
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

  5 in total
  34 in total

1.  Estimating HCV prevalence at the state level: a call to increase and strengthen current surveillance systems.

Authors:  Rachel Hart-Malloy; Alvaro Carrascal; A Gregory Dirienzo; Colleen Flanigan; Kristi McClamroch; Lou Smith
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

2.  Toward a more accurate estimate of the prevalence of hepatitis C in the United States.

Authors:  Brian R Edlin; Benjamin J Eckhardt; Marla A Shu; Scott D Holmberg; Tracy Swan
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

Review 3.  Estimating the true prevalence of hepatitis C in rhode island.

Authors:  Elizabeth N Kinnard; Lynn E Taylor; Omar Galárraga; Brandon D L Marshall
Journal:  R I Med J (2013)       Date:  2014-07-01

4.  Correlates of Hepatitis C Virus Infection in the Targeted Testing Program of the New York City Jail System.

Authors:  Matthew J Akiyama; Fatos Kaba; Zachary Rosner; Howard Alper; Aimee Kopolow; Alain H Litwin; Homer Venters; Ross MacDonald
Journal:  Public Health Rep       Date:  2016-12-14       Impact factor: 2.792

5.  Prevalence and correlates of hepatitis C virus infection among inmates at two New York State correctional facilities.

Authors:  Kimberly J Alvarez; Montina Befus; Carolyn T A Herzig; Elaine Larson
Journal:  J Infect Public Health       Date:  2014-08-30       Impact factor: 3.718

6.  Lower liver-related death in African-American women with human immunodeficiency virus/hepatitis C virus coinfection, compared to Caucasian and Hispanic women.

Authors:  Monika Sarkar; Peter Bacchetti; Audrey L French; Phyllis Tien; Marshall J Glesby; Marek Nowicki; Michael Plankey; Stephen Gange; Gerald Sharp; Howard Minkoff; Marion G Peters
Journal:  Hepatology       Date:  2012-08-27       Impact factor: 17.425

Review 7.  Global control of hepatitis C: where challenge meets opportunity.

Authors:  David L Thomas
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

8.  Hepatitis C screening: getting it right.

Authors:  Brian R Edlin
Journal:  Hepatology       Date:  2012-12-24       Impact factor: 17.425

9.  Direct-acting antiviral agents in patients with hepatitis C cirrhosis.

Authors:  Gene Y Im; Douglas T Dieterich
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-11

Review 10.  Murine models of hepatitis C: what can we look forward to?

Authors:  Markus von Schaewen; Alexander Ploss
Journal:  Antiviral Res       Date:  2014-01-24       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.